These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31137917)

  • 1. From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs.
    Lazarovici P; Marcinkiewicz C; Lelkes PI
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31137917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characteristic of snake venom disintegrins: potential therapeutic implication.
    Marcinkiewicz C
    Curr Pharm Des; 2005; 11(7):815-27. PubMed ID: 15777236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of eptifibatide.
    Phillips DR; Scarborough RM
    Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Snake venom probes of platelet adhesion receptors and their ligands.
    Wijeyewickrema LC; Berndt MC; Andrews RK
    Toxicon; 2005 Jun; 45(8):1051-61. PubMed ID: 15922774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of a new RGD/KGD-containing dimeric disintegrin, piscivostatin, from the venom of Agkistrodon piscivorus piscivorus: the unique effect of piscivostatin on platelet aggregation.
    Okuda D; Morita T
    J Biochem; 2001 Sep; 130(3):407-15. PubMed ID: 11530017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel α
    Kuo YJ; Chung CH; Pan TY; Chuang WJ; Huang TF
    Toxins (Basel); 2019 Dec; 12(1):. PubMed ID: 31877725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent.
    Kuo YJ; Chung CH; Huang TF
    Toxins (Basel); 2019 Jun; 11(7):. PubMed ID: 31247995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
    Huang TF; Chang CH; Ho PL; Chung CH
    Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of eptifibatide.
    Scarborough RM
    Am Heart J; 1999 Dec; 138(6 Pt 1):1093-104. PubMed ID: 10577440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function correlations of snake venom disintegrins.
    Calvete JJ
    Curr Pharm Des; 2005; 11(7):829-35. PubMed ID: 15777237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review.
    Schönthal AH; Swenson SD; Chen TC; Markland FS
    Biochem Pharmacol; 2020 Nov; 181():114149. PubMed ID: 32663453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Snake venoms and the hemostatic system.
    Markland FS
    Toxicon; 1998 Dec; 36(12):1749-800. PubMed ID: 9839663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S; Lu X; Kakkar VV; Authi KS
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Based Adhesion Assays for Isolation of Snake Venom's Integrin Antagonists.
    Lazarovici P; Marcinkiewicz C; Lelkes PI
    Methods Mol Biol; 2020; 2068():205-223. PubMed ID: 31576530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-platelet effect of cumanastatin 1, a disintegrin isolated from venom of South American Crotalus rattlesnake.
    Da Silva M; Lucena S; Aguilar I; Rodríguez-Acosta A; Salazar AM; Sánchez EE; Girón ME; Carvajal Z; Arocha-Piñango CL; Guerrero B
    Thromb Res; 2009 Mar; 123(5):731-9. PubMed ID: 18835011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
    Gilchrist IC
    Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.